{"id":"https://openalex.org/W4389032151","doi":"https://doi.org/10.1093/ofid/ofad500.1736","title":"2113. Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints","display_name":"2113. Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints","publication_year":2023,"publication_date":"2023-11-27","ids":{"openalex":"https://openalex.org/W4389032151","doi":"https://doi.org/10.1093/ofid/ofad500.1736"},"language":"en","primary_location":{"id":"doi:10.1093/ofid/ofad500.1736","doi":"https://doi.org/10.1093/ofid/ofad500.1736","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofad500.1736","pdf_url":"https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.1736/53772442/ofad500.1736.pdf","source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.1736/53772442/ofad500.1736.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5051510167","display_name":"Cecilia Godoy Carvalhaes","orcid":"https://orcid.org/0000-0002-2734-3754","observed_orcids":["https://orcid.org/0000-0002-2734-3754"]},"institutions":[{"id":"https://openalex.org/I4210121169","display_name":"JMI Laboratories","ror":"https://ror.org/02qv6pw23","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210121169"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cecilia G Carvalhaes","raw_affiliation_strings":["JMI Laboratories , North Liberty, IA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"JMI Laboratories , North Liberty, IA","institution_ids":["https://openalex.org/I4210121169"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073303672","display_name":"Paul R. Rhomberg","orcid":"https://orcid.org/0000-0001-6798-7653","observed_orcids":["https://orcid.org/0000-0001-6798-7653"]},"institutions":[{"id":"https://openalex.org/I4210121169","display_name":"JMI Laboratories","ror":"https://ror.org/02qv6pw23","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210121169"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul Rhomberg","raw_affiliation_strings":["JMI Laboratories , North Liberty, IA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"JMI Laboratories , North Liberty, IA","institution_ids":["https://openalex.org/I4210121169"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012264366","display_name":"Abby L Klauer","orcid":"https://orcid.org/0000-0002-9881-8286","observed_orcids":["https://orcid.org/0000-0002-9881-8286"]},"institutions":[{"id":"https://openalex.org/I4210121169","display_name":"JMI Laboratories","ror":"https://ror.org/02qv6pw23","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210121169"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Abby L Klauer","raw_affiliation_strings":["JMI Laboratories , North Liberty, IA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"JMI Laboratories , North Liberty, IA","institution_ids":["https://openalex.org/I4210121169"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113865393","display_name":"Beth Hatch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210121169","display_name":"JMI Laboratories","ror":"https://ror.org/02qv6pw23","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210121169"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Beth Hatch","raw_affiliation_strings":["JMI Laboratories , North Liberty, IA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"JMI Laboratories , North Liberty, IA","institution_ids":["https://openalex.org/I4210121169"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5045551151","display_name":"Mariana Castanheira","orcid":"https://orcid.org/0000-0003-0126-1782","observed_orcids":["https://orcid.org/0000-0003-0126-1782"]},"institutions":[{"id":"https://openalex.org/I4210121169","display_name":"JMI Laboratories","ror":"https://ror.org/02qv6pw23","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210121169"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mariana Castanheira","raw_affiliation_strings":["JMI Laboratories , North Liberty, IA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"JMI Laboratories , North Liberty, IA","institution_ids":["https://openalex.org/I4210121169"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210121169"],"apc_list":{"value":3676,"currency":"USD","value_usd":3676},"apc_paid":{"value":3676,"currency":"USD","value_usd":3676},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.22271992,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"10","issue":"Supplement_2","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10150","display_name":"Antifungal resistance and susceptibility","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10150","display_name":"Antifungal resistance and susceptibility","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10147","display_name":"Antibiotic Resistance in Bacteria","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2726","display_name":"Microbiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11900","display_name":"Fungal Plant Pathogen Control","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1110","display_name":"Plant Science"},"field":{"id":"https://openalex.org/fields/11","display_name":"Agricultural and Biological Sciences"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/isavuconazole","display_name":"isavuconazole","score":0.9990000128746033},{"id":"https://openalex.org/keywords/aspergillus-fumigatus","display_name":"Aspergillus fumigatus","score":0.9940000176429749},{"id":"https://openalex.org/keywords/invasive-aspergillosis","display_name":"invasive aspergillosis","score":1.0},{"id":"https://openalex.org/keywords/azole-resistance","display_name":"azole resistance","score":0.8579999804496765},{"id":"https://openalex.org/keywords/clinical-breakpoints","display_name":"clinical breakpoints","score":0.6880000233650208},{"id":"https://openalex.org/keywords/voriconazole","display_name":"voriconazole","score":0.9390000104904175},{"id":"https://openalex.org/keywords/itraconazole","display_name":"itraconazole","score":0.9990000128746033},{"id":"https://openalex.org/keywords/posaconazole","display_name":"posaconazole","score":1.0},{"id":"https://openalex.org/keywords/antifungal-susceptibility","display_name":"antifungal susceptibility","score":0.753000020980835},{"id":"https://openalex.org/keywords/epidemiological-cut-off","display_name":"epidemiological cut-off","score":0.640999972820282},{"id":"https://openalex.org/keywords/maldi-tof-ms-identification","display_name":"MALDI-TOF identification","score":0.6420000195503235},{"id":"https://openalex.org/keywords/geographic-distribution-of-resistance","display_name":"geographic distribution of resistance","score":0.47999998927116394},{"id":"https://openalex.org/keywords/clsi","display_name":"CLSI","score":0.3869999945163727}],"concepts":[{"id":"https://openalex.org/C2778566413","wikidata":"https://www.wikidata.org/wiki/Q906453","display_name":"Posaconazole","level":4,"score":0.7063367962837219},{"id":"https://openalex.org/C2780950330","wikidata":"https://www.wikidata.org/wiki/Q19903614","display_name":"Broth microdilution","level":4,"score":0.6491382122039795},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5994443893432617},{"id":"https://openalex.org/C2779787849","wikidata":"https://www.wikidata.org/wiki/Q134359","display_name":"Aspergillus fumigatus","level":2,"score":0.5894932150840759},{"id":"https://openalex.org/C2777071850","wikidata":"https://www.wikidata.org/wiki/Q411229","display_name":"Itraconazole","level":3,"score":0.5583218336105347},{"id":"https://openalex.org/C2780690907","wikidata":"https://www.wikidata.org/wiki/Q412236","display_name":"Voriconazole","level":3,"score":0.5304479002952576},{"id":"https://openalex.org/C2780315139","wikidata":"https://www.wikidata.org/wiki/Q419639","display_name":"Azole","level":3,"score":0.4729960858821869},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.416719913482666},{"id":"https://openalex.org/C2779548794","wikidata":"https://www.wikidata.org/wiki/Q578726","display_name":"Antifungal","level":2,"score":0.26310300827026367},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.22961199283599854},{"id":"https://openalex.org/C176947019","wikidata":"https://www.wikidata.org/wiki/Q597889","display_name":"Minimum inhibitory concentration","level":3,"score":0.18983420729637146},{"id":"https://openalex.org/C4937899","wikidata":"https://www.wikidata.org/wiki/Q68541106","display_name":"Antimicrobial","level":2,"score":0.16794756054878235},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.08672833442687988}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1093/ofid/ofad500.1736","doi":"https://doi.org/10.1093/ofid/ofad500.1736","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofad500.1736","pdf_url":"https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.1736/53772442/ofad500.1736.pdf","source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10678784","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10678784","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10678784/pdf/ofad500.1736.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infect Dis","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1093/ofid/ofad500.1736","doi":"https://doi.org/10.1093/ofid/ofad500.1736","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofad500.1736","pdf_url":"https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.1736/53772442/ofad500.1736.pdf","source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4389032151.pdf","grobid_xml":"https://content.openalex.org/works/W4389032151.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4389031978","https://openalex.org/W4311749408","https://openalex.org/W2139467279","https://openalex.org/W2791446090","https://openalex.org/W4378222389","https://openalex.org/W4403972730","https://openalex.org/W2160243152","https://openalex.org/W2189516087","https://openalex.org/W4311615392","https://openalex.org/W2598411000"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Isavuconazole":[2],"(ISC)":[3],"was":[4,51,200,228],"approved":[5],"by":[6,34,53,103,110,140,217],"the":[7,16,55,208,248,283,293,333],"US":[8],"FDA":[9],"and":[10,43,94,108,116,179,188,221,239,258,265,269,318,335],"is":[11,28],"considered":[12],"first-line":[13],"therapy":[14],"for":[15,300],"treatment":[17],"of":[18,41,65,211,247,272,332,341],"invasive":[19],"aspergillosis":[20],"(IA).":[21],"Azole":[22,232],"resistance":[23],"in":[24,70,77,202,230,292,326],"Aspergillus":[25],"fumigatus":[26],"(AFM)":[27],"a":[29,126],"growing":[30],"concern,":[31],"mainly":[32],"caused":[33],"mutations":[35],"within":[36],"CYP51":[37,138,241,252,277,347,351],"genes.":[38],"The":[39,197],"activity":[40,152,233,328],"ISC":[42,58,146,257,264,323],"other":[44,154,279,353],"azoles":[45,155],"against":[46,156,235,329,338],"AFM":[47,67,157,204,227,250,274,286,330,343],"causing":[48],"IA":[49],"worldwide":[50],"evaluated":[52],"applying":[54],"new":[56],"CLSI":[57,111,114,244],"clinical":[59],"breakpoints":[60],"(BP).":[61],"Methods":[62],"A":[63],"total":[64],"846":[66],"collected":[68],"(1/patient)":[69],"2017\u20132021":[71],"from":[72],"44":[73],"medical":[74],"centers":[75],"located":[76],"North":[78],"America":[79,96],"(NA;":[80],"n=282;":[81],"18":[82],"centers),":[83,88,93],"Europe":[84],"(EU;":[85],"n=449;":[86],"17":[87],"Asia-Pacific":[89],"(AP;":[90],"n=102;":[91],"8":[92,306,311,316],"Latin":[95],"(LA,":[97],"n=13;":[98],"1":[99,133,163],"center)":[100],"were":[101,120,135,260],"identified":[102],"MALDI-TOF":[104],"MS":[105],"and/or":[106],"sequencing":[107],"tested":[109],"broth":[112],"microdilution.":[113],"BP":[115],"epidemiological":[117],"cut-off":[118],"values":[119],"applied":[121],"where":[122],"available.":[123],"Isolates":[124],"displaying":[125,276,345],"non-wildtype":[127],"(NWT)":[128],"phenotype":[129,199],"to":[130,137,153,256,262],"at":[131,161,190,282],"least":[132],"azole":[134],"submitted":[136],"analysis":[139],"whole":[141],"genome":[142],"sequencing.":[143],"Results":[144],"Overall,":[145],"(MIC50/90,":[147],"0.5/1":[148],"mg/L)":[149,184],"showed":[150,207],"similar":[151],"(Table),":[158],"inhibiting":[159],"93.4%":[160],"\u2264":[162],"mg/L":[164],"(CLSI-approved":[165],"susceptible":[166],"[S]":[167],"BP).":[168],"Voriconazole":[169],"(VRC;":[170],"MIC50/90,":[171,176,182],"0.5/0.5":[172],"mg/L),":[173,178],"itraconazole":[174],"(ITC;":[175],"1/1":[177],"posaconazole":[180],"(PSC;":[181],"0.25/0.5":[183],"inhibited":[185,267],"91.6%,":[186],"92.0%,":[187],"97.2%":[189],"their":[191],"respective":[192,284],"S":[193,255,261],"or":[194,349],"wildtype":[195,346],"criteria.":[196],"AZ-NWT":[198,212,226,236,249,273,342],"detected":[201],"88":[203],"(10.4%);":[205],"NA":[206],"highest":[209],"frequency":[210],"isolates":[213,237,275,287,344],"(31;":[214],"11.0%),":[215],"followed":[216],"EU":[218],"(48;":[219],"10.7%)":[220],"AP":[222],"(9;":[223],"8.8%).":[224],"No":[225],"noted":[229],"LA.":[231],"varied":[234],"with":[238],"without":[240,251],"alterations.":[242],"Applying":[243],"BPs,":[245],"43.9%":[246],"alteration":[253],"remained":[254,336],"73.2%":[259],"VRC.":[263],"VRC":[266],"46.7%":[268],"43.3%,":[270],"respectively,":[271],"alterations":[278,352],"than":[280,354],"L98H/TR34":[281,289],"BP.":[285],"carrying":[288,350],"(17":[290],"occurrences)":[291],"CYP51A":[294],"sequence":[295],"displayed":[296],"elevated":[297],"MIC":[298],"ranges":[299],"all":[301],"azoles:":[302],"ISC,":[303],"2\u2013":[304,314],">":[305,310,315,339],"mg/L;":[307,312,317],"VRC,":[308],"1\u2013":[309],"ITC,":[313],"PSC,":[319],"0.5\u20134":[320],"mg/L.":[321],"Conclusion":[322],"demonstrated":[324],"potent":[325],"vitro":[327],"regardless":[331],"region":[334],"active":[337],"40%":[340],"sequences":[348],"L98H/TR34.":[355],"Disclosures":[356],"Cecilia":[357],"G.":[358],"Carvalhaes,":[359],"MD,":[360],"PhD,":[361,402],"AbbVie:":[362,403],"Grant/Research":[363,365,367,369,371,373,380,382,384,391,398,404,406,408,410,412,414,416,418,420,422],"Support|bioMerieux:":[364,407],"Support|Cipla:":[366,409],"Support|CorMedix:":[368,411],"Support|Melinta:":[370,381,415],"Support|Pfizer:":[372,383,419],"Support":[374,385,392,399,423],"Paul":[375],"Rhomberg,":[376],"BS,":[377,389],"MT(ASCP),":[378,396],"bioMerieux:":[379],"Abby":[386],"L.":[387],"Klauer,":[388],"Pfizer:":[390,397],"Beth":[393],"Hatch,":[394],"BA":[395],"Mariana":[400],"Castanheira,":[401],"Support|Basilea:":[405],"Support|Entasis:":[413],"Support|Paratek:":[417],"Support|Shionogi:":[421]},"counts_by_year":[],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2023-11-27T00:00:00"}